🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Australia / NCT06360939
Recruiting Not applicable

Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease

NCT06360939 · tracked via the Priya Life Science Australia tracker
Phase
Not applicable
Started
2025-11-03
Last updated
2026-02-18

Condition(s) studied

Ventricular TachycardiaCardiomyopathiesArrhythmias, CardiacVentricular Arrythmia

Investigational drug(s) / intervention(s)

SBRTCA

SBRT: Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization

CA: CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.

Study summary

The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:

* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months
* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of 1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI 2. myocardial hypertrophy 3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography) 2. Recurrent monomorphic VT which can include 1. at least one episode of VT treated by ICD and/or 2. sustained VT (lasting \>30s) and/or 3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS) 3. PAINESD score of ≥9 points and/or at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and/or mortality after CA. Exclusion Criteria: 1. Age \< 18 years 2. Life expectancy \< 3 months 3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist. 4. Unwilling or unable to provide consent 5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome) 6. Contraindications to radiotherapy as deemed by referring physician and/or radiation oncologist 7. Pregnancy or breast feeding

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Westmead Hospital Westmead Australia Recruiting

More Western Sydney Local Health District trials in Australia

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06360939 on ClinicalTrials.gov ↗ ← All trials in Australia